AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury News-Medical.net AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center ... |
